Veterinary Regenerative Medicine Market Size, Share & Trends Analysis Report By Animal Type (Small Animals, Large Animals), By Product, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Veterinary Regenerative Medicine Market Size, Share & Trends Analysis Report By Animal Type (Small Animals, Large Animals), By Product, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Veterinary Regenerative Medicine Market Growth & Trends

The global veterinary regenerative medicine market size is expected to reach USD 640.16 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 12.54% from 2023 to 2030. The key factors driving the growth include the rising incidence of soft tissue injuries and osteoarthritis in animals, rising pet industry expenditure, expanding access to veterinary services, and several advantages of animal stem cell therapy. Thirty-three percent of training losses and waste in sport horses across all categories are attributable to soft tissue injuries, which can damage any tendon or ligament. These injuries account for 13% to 18% of horses who need rest and time off. An increase in acute workload and fitness level, among other things, are two major factors that contribute to soft tissue injury in horses.

Animal stem cell therapy has several benefits, further fueling the market’s growth. These days, animal stem cell therapy is very popular due to its capacity to utilize an animal's own stem cells to prolong treatment for a disease or illness. Animals who receive this therapy live much longer. Many health problems, including arthritis, degenerative joint disorders, and ligament and tendon injuries in animals, have seen a large increase in occurrences in recent years. Cats, dogs, and horses are frequently treated with stem cell treatment. This factor is supporting the growth of the market for veterinary regenerative medicine worldwide.

Companies are focusing on animal stem cell therapies to reduce the prevalence of disease in animals and improve the animal's quality of life. Animal stem cell research has tremendous potential for understanding fundamental mechanisms of animal development, as well as for treating a wide range of diseases and disorders in animals. All of these factors work as drivers for the market for veterinary regenerative medicine to grow rapidly. Furthermore, increased investment in R&D activities in the animal stem cell therapy market is one of the primary factors driving the market growth.

Pet owners are reluctant to spend a sizable number of money on their pet's treatment because animal stem cell therapy is fairly expensive. Also, many conventional veterinary hospitals are not equipped to treat animals with stem cells. Although pet insurance companies pay for stem cell treatments, they do not pay for additional procedures like retreatment. A significant percentage of pet owners do not have pet insurance, which will limit the future growth of the market for animal regenerative medicine.

In veterinary medicine, regenerative therapies such as mesenchymal stem cells, platelet-rich plasma, and autologous serum products are becoming increasingly popular for treating horses and dogs. The main objectives of regenerative therapies are to control immune responses, stop the immune system from causing additional tissue damage, and administer trophic and growth hormones to promote endogenous tissue regeneration. The FDA has not yet approved any cell-based regenerative medicines.

A lack of standardization in the tissue origin, the timing of injection, dosing, and use of adjunct therapies may be the cause of the lack of agreement on treatment protocols for MSC therapy in veterinary medicine, which may account for variations in treatment efficacy reported for different clinical trials. For the treatment of tendinitis, osteoarthritis, and desmitis, MSC therapy has the most clinical evidence of clinical efficacy. When tendon injuries are treated with MSCs in horses and dogs, the tissue composition and fiber alignment are improved, and the recurrence rates are reduced.

Veterinary Regenerative Medicine Market Report Highlights

• The stem cells segment is expected to grow for the highest revenue share over the forecast period
• Orthopedics dominated the market in 2022 with the largest revenue share of over 40.0% due to the increasing prevalence of arthritis in pets
• The small animals segment accounted for the highest revenue share in 2022. The increasing adoption of pets and increased costs for their well-being and health is expected to boost the market growth
• The veterinary hospitals & clinics segment accounted for the highest revenue share in 2022. In veterinary hospitals and clinics, the increased number of patients visiting these facilities for stem cell therapy and the growing number of veterinarians, which is projected to support segment growth
• North America is expected to dominate the veterinary regenerative medicine industry over the forecast period due to the increased awareness rate of the therapy
• Some of the key players are Boehringer Ingelheim International GmbH, Zoetis, Vetbiologics, and Animal Cell Therapies, Inc.

Please note The report will be delivered in 3-8 business days upon order notification.